Company Encyclopedia
View More
name
Aerovate Therapeutics
AVTE.US
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
1.902 T
AVTE.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    40,047 Shares in Aerovate Therapeutics, Inc. $AVTE Acquired by Nuveen LLC

    Nuveen LLC has acquired 40,047 shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) valued at approximately $101,000, representing about 0.14% of the company. Other institutional investors have also adjusted their stakes, with Two Sigma Advisers LP increasing its holdings by 38.5%. Aerovate Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing treatments for rare cardiopulmonary diseases. The stock opened at $7.77, with a market cap of $225.21 million and a price-to-earnings ratio of -2.60.

    Market Beat·
    US
    AVTE
    0.00%
    Market Beat·
    US
    AVTE
    0.00%

    Renaissance Technologies LLC Buys 26,700 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

    Renaissance Technologies LLC increased its stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) by 149.2% in Q4, acquiring an additional 26,700 shares, bringing its total to 44,600 shares valued at $118,000. Other institutional investors also boosted their positions significantly. Aerovate's stock opened at $10.09, with a market cap of $292.46 million and a PE ratio of -3.37. The company recently reported an EPS of ($3.15), surpassing estimates, and announced a dividend of $84.00 paid on April 28th.

    Market Beat·
    US
    AVTE
    0.00%
    Market Beat·
    US
    AVTE
    0.00%

    JPMorgan Chase & Co. Has $178,000 Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

    JPMorgan Chase & Co. increased its stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) by 1,021.1% in Q4, owning 67,165 shares valued at $178,000. Other institutional investors also acquired stakes in the company. Aerovate's stock rose 24.8%, opening at $12.48, with a market cap of $361.73 million. The company reported a quarterly EPS of ($3.15), exceeding estimates. Aerovate focuses on developing treatments for rare cardiopulmonary diseases and recently announced a dividend of $84.00.

    Market Beat·
    US
    AVTE
    0.00%
    US
    JPM
    +0.36%
    Market Beat·
    US
    AVTE
    0.00%
    US
    JPM
    +0.36%

    Investors Buy Large Volume of Call Options on Aerovate Therapeutics (NASDAQ:AVTE)

    Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the target of unusually large options trading activity on Monday. Stock investors bought 9,373 call options on the stock. This is an increase of approximately 2,291% compared to the average volume of 392 call options.

    Market Beat·
    US
    AVTE
    0.00%
    Market Beat·
    US
    AVTE
    0.00%

    Aerovate Therapeutics, Inc. (NASDAQ:AVTE) to Issue Dividend of $2.40

    Aerovate Therapeutics, Inc. (NASDAQ:AVTE) announced a dividend of $2.40 per share, payable on April 28th to shareholders of record as of April 25th. The ex-dividend date is April 29th. The company's stock opened at $2.68, with a market cap of $77.68 million. Aerovate reported an EPS of ($0.09) for the last quarter, surpassing estimates. Analysts project a fiscal year EPS of -2.64. Aerovate focuses on developing treatments for rare cardiopulmonary diseases, particularly AV-101 for pulmonary arterial hypertension, currently in Phase 2b/Phase 3 trials.

    Market Beat·
    US
    AVTE
    0.00%
    Market Beat·
    US
    AVTE
    0.00%
    © 2025 Longbridge｜Disclaimer